Adaptive Biotechnologies (ADPT) COO sells shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of option exercises and related stock sales in common stock. Over March 24–26, she exercised stock options to acquire a total of 44,166 shares of common stock at an exercise price of $7.27 per share. She then sold 57,180 shares in open-market transactions at weighted average prices ranging from $13.45 to $14.49 per share. Following these transactions, she directly holds 468,892 shares of Adaptive Biotechnologies common stock. The filing notes that all transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RUBINSTEIN JULIE

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WASHINGTON 98109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/24/2026		M(1)		14,722	A	$7.27	496,628	D
Common Stock	03/24/2026		S(1)		19,060	D	$13.7(2)	477,568	D
Common Stock	03/25/2026		M(1)		14,722	A	$7.27	492,290	D
Common Stock	03/25/2026		S(1)		19,060	D	$14.27(3)	473,230	D
Common Stock	03/26/2026		M(1)		14,722	A	$7.27	487,952	D
Common Stock	03/26/2026		S(1)		19,060	D	$14.12(4)	468,892	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.27	03/24/2026		M(1)			14,722	(5)	02/07/2029	Common Stock	14,722	$0	184,773	D
Stock Option (right to buy)	$7.27	03/25/2026		M(1)			14,722	(5)	02/07/2029	Common Stock	14,722	$0	170,051	D
Stock Option (right to buy)	$7.27	03/26/2026		M(1)			14,722	(5)	02/07/2029	Common Stock	14,722	$0	155,329	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.45 to $13.92, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.98 to $14.49, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.82 to $14.36, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

5. The option is fully vested and exercisable.

	/s/ Julie Rubinstein by Kyle Piskel, Attorney-in-Fact	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Adaptive Biotechnologies (ADPT) executive Julie Rubinstein report in this Form 4?

Julie Rubinstein reported option exercises and share sales. She exercised stock options for 44,166 Adaptive Biotechnologies common shares at $7.27 per share and sold 57,180 shares in open-market transactions, all under a pre-arranged Rule 10b5-1 trading plan.

How many Adaptive Biotechnologies (ADPT) shares did Julie Rubinstein sell?

Julie Rubinstein sold 57,180 common shares. The shares were sold in multiple open-market transactions at weighted average prices between $13.45 and $14.49 per share over three days, as detailed in the Form 4 filing’s transaction table and footnotes.

At what price did Julie Rubinstein exercise Adaptive Biotechnologies (ADPT) stock options?

She exercised options at an exercise price of $7.27 per share. Across three transactions, 44,166 option-based shares of Adaptive Biotechnologies common stock were acquired at this price before related open-market sales disclosed in the same Form 4.

How many Adaptive Biotechnologies (ADPT) shares does Julie Rubinstein own after these transactions?

Julie Rubinstein directly owns 468,892 common shares after the trades. This post-transaction holding reflects her remaining stake following the reported option exercises and sales, as shown in the total shares following transaction fields in the Form 4.

Were Julie Rubinstein’s Adaptive Biotechnologies (ADPT) share sales pre-planned?

Yes, the sales were made under a Rule 10b5-1 trading plan. A footnote states the transactions were effected pursuant to a plan adopted on November 18, 2025, indicating the trades were scheduled in advance rather than decided at the time of sale.

What type of securities did Julie Rubinstein exercise and sell for Adaptive Biotechnologies (ADPT)?

She exercised stock options and sold common stock. The filing lists derivative transactions in stock options, converting into 44,166 shares of common stock, followed by open-market sales totaling 57,180 shares of Adaptive Biotechnologies common stock.